What is it prescribed for?
ALYFTREK is prescribed for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have certain specific genetic mutations. This medication helps improve lung function and reduce symptoms of the disease. ALYFTREK was approved on December 20, 2024.
What is the name of the drug and what does it do?
The drug is called ALYFTREK (pronounced: AL-if-trek), with the generic names vanzacaftor, tezacaftor, and deutivacaftor. These ingredients work together to target the underlying cause of cystic fibrosis. Cystic fibrosis is caused by mutations in the CFTR gene, which affects how chloride and water move in and out of cells. ALYFTREK helps the CFTR protein function better, reducing the buildup of mucus in the lungs and other organs.
How does it work?
ALYFTREK combines three active ingredients: vanzacaftor and tezacaftor, which help correct the shape of the defective CFTR protein and allow it to reach the cell surface; and deutivacaftor, which boosts the activity of the CFTR protein, improving its ability to transport chloride ions across cell membranes. Together, these actions improve respiratory and digestive functions in patients with CF.
What did the research discover?
Clinical trials showed that ALYFTREK significantly improved lung function in patients with specific CFTR gene mutations. Participants experienced fewer pulmonary exacerbations (lung infections or worsening symptoms) compared to those who did not take the drug. Improvements were also noted in overall quality of life, with reductions in mucus buildup and better breathing capabilities.
What are shome of the side effects?
Some of the side effects reported during the trials include:
- Elevated liver enzymes (a sign of liver stress or damage)
- Headache
- Abdominal pain
- Diarrhea
- Dizziness
- Rash
The medication also carries a warning for potential drug-induced liver injury. Liver function tests should be monitored before starting and during treatment.
What are the dosage recommendations and how is it prescribed?
ALYFTREK is available in tablet form and is typically taken once daily with fat-containing food to enhance absorption. The dosage depends on the patient’s age and specific CFTR gene mutations. Doctors will determine the exact dose based on individual needs and monitor for any side effects or required adjustments.
Source:
Vertex Pharmaceuticals. Highlights of prescribing information for ALYFTREK. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218730s000lbl.pdf
